Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nrf2-siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Intraperitoneal
01
Overview
Nrf2-siRNA is a small interfering RNA (siRNA) designed to silence the expression of the Nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor encoded by the NFE2L2 gene. Nrf2 is a master regulator of the cellular antioxidant response and detoxification enzymes, and its overexpression in various malignancies, such as esophageal cancer, is associated with tumor growth, chemoresistance, and poor prognosis. Nrf2-siRNA functions through the RNA interference (RNAi) pathway, where it mediates the sequence-specific degradation of Nrf2 mRNA, leading to a significant reduction in Nrf2 protein levels. In preclinical studies, treatment with Nrf2-siRNA has been shown to inhibit cancer cell proliferation and induce cell cycle arrest at the G1 phase, suggesting that targeting the Nrf2 pathway may be a viable therapeutic strategy for improving outcomes in patients with Nrf2-overexpressing tumors.
- Other names
- siRNA targeting Nrf2NFE2L2-siRNANFE-2L2-siRNANFE 2L2-siRNANrf2 small interfering RNANrf-2 small interfering RNANrf 2 small interfering RNA
02
Targets
NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on Nrf2-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nrf2-siRNA.